



natural |  **BioProspect**
Limited

selection

General Meeting

June 3, 2010

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements regarding the company's business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing the company's goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising products that can be proven to be safe and effective for use as products in public health, pest management and for human and animal health therapeutics, and in the endeavor of building a business around such products and services. Actual results could differ materially from those discussed in this presentation. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the BioProspect Limited Annual Report for the year ended June 30, 2009, copies of which are available from the company or at www.biopropect.com.

Project Update



AGRI PROTM

Commercialisation Initiated

- BioProspect commercialising new equine healthcare products *GI-Guard*[™] Oral Paste and *AGRIPRO*[™] Topical Gel, based on CGNC (conifer green needle complex)
- Targeting A\$15bn global animal health products market



AGRIPRO



GIG  GUARD

GASTRO INTESTINAL CARE

Marketing Strategy Developed

- Marketing strategy to commercialise under the *AGRIPRO*[™] corporate brand
- Target companion animals initially
- Aim to enter into distribution and licensing arrangements with major local and international commercial collaborators



AGRIPRO



Regulatory Pathway Defined

- New Australian Pesticides & Veterinary Medicines Authority (APVMA) guidelines for natural veterinary health products for use in companion animals cut registration timeframe to around 12 months
- Category 2 for TGA approved actives
 - Part 2: Product Chemistry
 - Part 8: Efficacy/Safety
 - Part 3: Toxicology NOT required
- Timeframe 10-12 months



DATA PART	MODULE	DESCRIPTION
Application form and Overview	Module 1	Screening
Part 2 Chemistry and manufacture	Module 2.2	Chemistry – Level 2
Part 8 Efficacy and target animal safety	Module 8.2	Efficacy and target animal safety – Level 2
	Module 11.2	Finalisation – Level 2
	Module 12	Data protection

REQUIREMENTS AND GUIDELINES FOR VETERINARY HERBAL REMEDIES

Safety/Efficacy Studies

- Safety studies successfully undertaken with both products: *GI-Guard*[™] Oral Paste & *AGRIPRO*[™] Topical Gel for Horses
- Additional efficacy studies planned to complete data package for product registration

Photo courtesy of SCEC Pty Ltd



GIG  **ARD**

GASTRO INTESTINAL CARE

Project Update

termilone[®]



Focus on *TERMILONE*[®] Formulations

- Eremophilone oil now registered as an active constituent with the APVMA
- Focus now on *TERMILONE*[®] formulations
- Aim to develop data package to support APVMA registration as a natural, environmentally friendly timber treatment and soil barrier against termites



Australian Government
Australian Pesticides and
Veterinary Medicines Authority

NOTICE OF APPROVAL OF AN ACTIVE CONSTITUENT

The Australian Pesticides and Veterinary Medicines Authority has granted, subject to certain conditions, your approval of Eremophilone oil active constituent for use in agricultural chemical products, the recorded particulars of which are set out below.

Approval Number:	63599
Approval Holder:	BIOPROSPECT LIMITED
Approval Holder's Address:	SUITE 6, LEVEL 3 320 ADELAIDE ST BRISBANE QLD 4000
Common Chemical Name:	Eremophilone oil

***TERMILONE*[®] TT – Laboratory Bioassays**


- Laboratory bioassay testing with *TERMILONE*[®] TT as a timber treatment – CSIRO
- Confirmed protection from *TERMILONE*[®] TT vs. *Coptotermes acinaciformis* in lab no-choice test



TERMILONE[®] TT – CSIRO Field Test, Darwin

- Confirmed effectiveness vs. *Coptotermes acinaciformis*
- Not effective against *Mastotermes darwiniensis*
- Next steps economic analysis & consideration of envelope treatment & field testing

% Mass Loss due to *C. acinaciformis*




TERMILONE[®] Laboratory Bioassay Testing

- University of Western Sydney bioassay testing shows product effective as soil barrier against *Nasutitermes exitiosus* and *Coptotermes acinaciformis* termite species

Fig 1. Set-up of horizontal assay tubes (25 mm diam. x 250 mm).



Fig 2. Set-up of vertical assay tubes (22 mm diam. x 190 mm) (modified after Su et al. 1995)



TERMILONE[®] Field Testing – soil application

- Two trials established in North Queensland vs. *C. acinaciformis*
- Colony treatment trial - initial results show higher concentrations required
- Soil barrier field trial results pending evaluation – 6 months after treatment



Manufacturing Study Progressing

- Pilot scale tests with Southern Cross University confirm conditions for optimal oil extraction
- Monitoring of commercial facility has confirmed suitable conditions for extraction of Eremophilone Oil
- Commercial scale operation planned to process timber collected in 2009



Economic Analysis of *TERMILONE*[®] Use

- Full economic analysis of *TERMILONE*[®] planned, pending completion of manufacturing and field testing programs
- Timber treatment & soil applied barrier two major uses for *TERMILONE*[®]



Other Uses for Eremophilone Oil

- Eremophilone oil also used as aromatic oil in fragrances & cosmetics & by products can be used for production of incense/joss sticks
- *Eremophila mitchellii* timber can be used as aromatic wood for furniture & art



re-gen



Brand & Product Development

- Novel products, brands developed to commercialise *REGEN*[™] and *DEMURE*[™] products in both Australian and overseas markets via online and over the counter sales



New Formulations

- New *REGEN*[™] Pain Relief Spray flagship product in range of *REGEN*[™] therapeutic products



Product Differentiation & IP Value

- *Transdermal Solvency™* and *Transdermal Permeating Complex™ (TPC™)* incorporated into *REGEN™* and *DEMURE™* products and marketing to support differentiation strategy
- Novel formulations with proprietary components used to enhance performance and strengthen intellectual property value



TGA Approvals for *REGEN*TM Therapeutics

- “Aust L” listing with the Australian Therapeutic Goods Administration (TGA) being progressed for *REGEN*TM therapeutic products



ARTG Certificate

Issued to
Re Gen Wellness Products Aust Pty Ltd
for approval to supply
Re-Gen Emu Oil Capsules

AUST Identifier: AUST L169721
AUST Start date: 10/03/2010
Product type: Listed Medicine

Manufacturer(s) Details
And of List holder trading as Bureau Veritas Pharmaceutical

EML Consulting Services Pty Ltd

GMP Pharmaceuticals Pty Limited

Sillicor Australia Pty Ltd.

Address	Manufacturing steps
Unit 1 8614 & 17/8 Leighton Place ASCQUITH, NSW, 2077 Australia	Testing chemical and physical
Unit 2 711 South Street MIDLANDRIDGE, NSW, 2114 Australia	Testing micro-bial
79 Amers Avenue CHERRYBROOK, NSW, 2143 Australia	Manufacture of dosage form Packaging and labelling Release for supply Secondary packaging
Unit C2 / 301 Park Road Eagons Park Estate EAGONS PARK, NSW, 2143 Australia	Testing micro-bial



Approvals for *DEMURE*[™] Skin Care Products

- Approvals being obtained with China's State Food and Drug Administration (SFDA) for *DEMURE*[™] skin care products




Illustration of mock up pack only



natural |  BioProspect
Limited
selection